- Home
- FLC vs EPIX Comparison
FLC vs EPIX Comparison
Compare FLC & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- EPIX
- Stock Information
- Founded
- FLC 2003
- EPIX 2009
- Country
- FLC United States
- EPIX Canada
- Employees
- FLC N/A
- EPIX N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- EPIX Health Care
- Exchange
- FLC Nasdaq
- EPIX Nasdaq
- Market Cap
- FLC 180.6M
- EPIX 209.4M
- IPO Year
- FLC N/A
- EPIX N/A
- Fundamental
- Price
- FLC $16.60
- EPIX $1.72
- Analyst Decision
- FLC
- EPIX Hold
- Analyst Count
- FLC 0
- EPIX 4
- Target Price
- FLC N/A
- EPIX $9.50
- AVG Volume (30 Days)
- FLC 37.8K
- EPIX 2.4M
- Earning Date
- FLC 01-01-0001
- EPIX 12-10-2024
- Dividend Yield
- FLC 6.64%
- EPIX N/A
- EPS Growth
- FLC N/A
- EPIX N/A
- EPS
- FLC N/A
- EPIX N/A
- Revenue
- FLC N/A
- EPIX N/A
- Revenue This Year
- FLC N/A
- EPIX N/A
- Revenue Next Year
- FLC N/A
- EPIX N/A
- P/E Ratio
- FLC N/A
- EPIX N/A
- Revenue Growth
- FLC N/A
- EPIX N/A
- 52 Week Low
- FLC $12.62
- EPIX $1.40
- 52 Week High
- FLC $15.45
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- FLC 35.64
- EPIX 23.15
- Support Level
- FLC $17.18
- EPIX $1.75
- Resistance Level
- FLC $17.18
- EPIX $1.89
- Average True Range (ATR)
- FLC 0.16
- EPIX 0.19
- MACD
- FLC -0.03
- EPIX -0.10
- Stochastic Oscillator
- FLC 7.94
- EPIX 7.36
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.